PlainRecalls
FDA Drug Moderate Class II Ongoing

Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5mg, 18 (3 x 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, Product of India, NDC 68462-467-06

Reported: June 12, 2024 Initiated: May 13, 2024 #D-0534-2024

Product Description

Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5mg, 18 (3 x 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, Product of India, NDC 68462-467-06

Reason for Recall

CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.

Details

Units Affected
2400 cartons
Distribution
US Nationwide.
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
Rizatriptan Benzoate Orally Disintegrating Tablets, USP 5mg, 18 (3 x 6) Unit-Dose Tablets, Manufactured for: Glenmark Pharmaceuticals Inc., USA Mahwah, NJ 07430, Product of India, NDC 68462-467-06. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 2400 cartons.
Why was this product recalled?
CGMP Deviations: N-Nitroso Desmethyl Rizatriptan Impurity results that are above the FDA acceptable limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on June 12, 2024. Severity: Moderate. Recall number: D-0534-2024.